Semaglutide biosimilar(Chengdu Bette)

司美格鲁肽生物类似药（成都倍特）

Report date: 2026/04/16 20:00:17

Base Information

Drug NameSemaglutide biosimilar(Chengdu Bette)
Drug Alias Namesemaglutida biosimilar索马鲁肽生物类似药semaglutidum biosimilar索玛鲁肽生物类似药司美鲁肽生物类似药 +[6] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsOverweightObesityDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesChengdu Bette Biological Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChengdu Bette Biological Pharmaceutical Co LtdChengdu Brilliant Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsOverweightObesityDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A